Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.
GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.
Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.
Alliance Pharma has launched Xonvea, a new prescription drug for the treatment of nausea and vomiting of pregnancy (NVP), in the UK.
Gilead Sciences is planning to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the US.
Civica Rx, the initiative earlier known as Project Rx, is the name of a new not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving medications.
Drugmaker Lupin has launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets for preventing pregnancy in the US.
Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure.
Accent Therapeutics has been launched with $40m Series A financing for precision cancer treatments targeting RNA-modifying proteins.
Alkermes has launched a new competitive awards program called the ALKERMES Pathways Research Awards Program to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.